Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aclidinium bromide 200 μg and 400 μg versus placebo in moderate to severe COPD
2009-011600-27Phase 3Completed
- Sponsor
- Almirall
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aclidinium in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Almirall. Primary endpoints: Change from baseline in morning pre-dose (trough) FEV1 at week 24 and Change from baseline in morning pre-dose (trough) FEV1 at week 12. Started Jun 2009; status: completed.
02
Drugs
aclidinium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2009-011600-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011600-27.